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For more than 50 years, small airways disease has been considered a key feature of chronic obstructive
pulmonary disease (COPD) and a major cause of airway obstruction. Both preventable and treatable,
small airways disease has important clinical consequences if left unchecked. Small airways disease is
associated with poor spirometry results, increased lung hyperinflation, and poor health status, making
the small airways an important treatment target in COPD. The early detection of small airways disease
remains the key barrier; if detected early, treatments designed to target small airways may help reduce
symptoms and allow patients to maintain their activities. Studies are needed to evaluate the possible
role of new drugs and novel drug formulations, inhalers, and inhalation devices for treating small
airways disease. These developments will help to improve our management of small airways disease in
patients with COPD.
ª 2021 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/) n Mayo Clin Proc. 2021;nn(n):1-16From the National Heart
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Aberdeen, UK (D.P.).F or more than 50 years, small airwaysdisease has been identified as a majorcause of airway obstruction, particularly
early in the course of chronic obstructive pul-
monary disease (COPD).1-4 Although some-
what underrecognized in daily clinical
practice,5 small airways disease is reported in
at least three-quarters of patients with
COPD.6 Indeed, given the difficulties in assess-
ing small airway abnormalities, which we
describe later in this article, it is likely that
small airways dysfunction is a common factor
in all patients with COPD, coexisting in
differing degrees with other phenotypic varia-
tions of this complex and heterogeneous
disease.
Also known as peripheral airways, the
small airways (<2 mm in diameter) include
bronchioles, terminal bronchioles, respiratory
bronchioles, alveolar ducts, and alveolar sacs
(Figure 1A). The term “small airways disease”
was first coined in 1968 and identified as the
major cause of airway resistance in patients
with obstructive lung disease.3 More recently,Mayo Clin Proc. n XXX 2021;nn(n):1-16 n https://doi.org/10.1016/j.
www.mayoclinicproceedings.org n ª 2021Mayo Foundation for Med
the CC BY license (http://creativecommons.org/licenses/by/4.0/).the role of small airways disease in the path-
ogenesis of COPD has been recognized by the
Global Initiative for Chronic Obstructive
Lung Disease (GOLD)7 and Interasma/the
World Allergy Organization.8
Notably, the documented prevalence of
small airways disease (74%-83%6,9) increases
with rising GOLD classification, indicating
that it is progressive and worsens with
increasing severity of COPD.6 Small airways
disease is particularly notable (w93%) in pa-
tients with a high effect of COPD on health
status and daily life.6 The fact that small air-
ways are involved in the development of
airflow limitation in both predominant
COPD phenotypesdemphysema and chronic
bronchitisdindicates their prominent role in
the pathogenesis of the condition.3,10,11METHODS
The aims of this focused review were to sum-
marize key information on the pathophysi-
ology of small airways disease, how it is
assessed, and why it is an importantmayocp.2021.03.016
ical Education and Research. Published by Elsevier Inc. This is an open access article under
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ARTICLE HIGHLIGHTS
d Small airways disease is a key feature of chronic obstructive
pulmonary disease (COPD) and a major cause of airway
obstruction.
d Patients with COPD and small airways disease have worse
spirometry results, more severe lung hyperinflation, and poorer
health status compared with those without small airways dis-
ease, making the small airways an important treatment target.
d In this article, we evaluate several new techniques that have the
potential to achieve the early detection of small airways disease.
d We review therapy options designed to target the small airways
that may help reduce symptoms and allow patients to maintain
their activities.
d Advances in our ability to assess the extent of small airways
involvement, as well as the use of novel drugs, formulations, and
inhalers that target the small airways, will help to improve our
management of small airways disease in patients with COPD.
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treatment target as well as to review available
treatments and future directions in the man-
agement of the condition. Studies included
in this article were identified by searching
the PubMed (MEDLINE) database, using
the search terms COPD AND (“small airway
disease” OR “small airways disease” OR
“small airway dysfunction” OR “small air-
ways dysfunction”) and by cross-referencing
citations in identified studies that were avail-
able in print or online, including relevant
studies in patients with asthma.
PATHOPHYSIOLOGY
Airway Remodeling, Mucus Plugging, and
Immune Cell Infiltration
In COPD, small airways disease is character-
ized by airway remodeling, mucus
plugging, and immune cell infiltration
(Figure 1B).4,12-14 Injury caused by factors
such as cigarette smoke or infection triggers
the wound healing process, resulting in an in-
crease in airwaywall thickness and therefore a
decrease in the airway lumen.4 Cigarette
smoking also induces hypersecretion of
mucus, leading to mucus plugging and phys-
ical blockage of airflow.4 This is compounded
by the effect of smoking in reducing ciliaMayo Clin Proc. n XXXlength in the small airways, leading to
decreased mucociliary clearance.4 Mucus
may also harbor pathogenic microorganisms
that promote inflammation and tissue
destruction.4 Immune cell infiltration in-
volves the recruitment of increased numbers
of macrophages, neutrophils, CD20þ B cells,
and CD4þ and CD8þ T cells to the small air-
ways,4 with CD8þ T cells hypothesized to be
the predominant inflammatory cells contrib-
uting to small airway obstruction and tissue
damage.12Evidence Early in the Course of COPD
Small airways disease is often evident before
the onset of symptoms or changes in spirom-
etry or imaging findings in COPD.5,15 The
small airways represent a “silent zone” in
the normal lung in which defects can accu-
mulate without being noticed; this finding
has led to the development of specialized
tests to detect early abnormalities in the
hope of preventing or delaying disease pro-
gression.13 However, traditional imaging
techniques may not be sufficiently sensitive
to identify the early stages of small airways
disease or to differentiate between the contri-
bution of small airways disease and emphy-
sema.13 Because extensive small airways
damage and obliteration can occur before it
is detectable with conventional spirometric
tests, spirometry is also of limited use as a
screening tool for early disease.5
Small airways disease may be a precursor
to emphysema.4,16 Very severe COPD is asso-
ciated with a marked reduction in both the
number of terminal bronchioles and the mini-
mal lumen caliber of those that remain.16
These changes can be present in regions of
the lungs not yet affected by emphysema, sug-
gesting that theymay begin at very early stages
in the natural history of COPD.16 Other
studies have reported that both small airways
disease and emphysema are associated with
decline in forced expiratory volume in 1 sec-
ond (FEV1), but small airways disease has a
greater role in the decline associated with
mild-to-moderate airflow limitation, which in-






























FIGURE 1. (A) Small airways in the respiratory system and (B) pathological abnormalities associated with small airways disease.
TARGETING SMALL AIRWAYS DISEASE IN COPDEffect of Small Airways Disease on
Hyperinflation
Pulmonary hyperinflation is a common
cause of dyspnea and functional limitation
in patients with COPD.19 Small airways dis-
ease can lead to expiratory flow limitation,
gas trapping within the lung and dynamic
hyperinflation.14,20 This is characterized by
flattening of the diaphragm, sternal bowing,
chest kyphosis, and enlarged intercostal
spaces, resulting in a barrel chest.21 Dynamic
hyperinflation develops as a result of expira-
tory airflow limitation coupled with
decreased exhalation time, for example, dur-
ing exercise, and is associated with decreased
inspiratory capacity and increased functional
residual capacity (Figure 2).19
Hyperinflation affects clinical outcomes
in COPD; for example, activity-related dys-
pnea associated with hyperinflation can
lead to a vicious cycle of activity avoid-
ance, physical deconditioning, and reducedMayo Clin Proc. n XXX 2021;nn(n):1-16 n https://doi.org/10.1016/j.
www.mayoclinicproceedings.orghealth-related quality of life.20 Indeed, dy-
namic hyperinflation and exercise limita-
tion are both independent predictors of
mortality in patients with COPD.19 Hyper-
inflation also has implications for the early
development of comorbidities such as car-
diovascular disease.20 Of particular
concern, hyperinflation impairs the me-
chanical function of the respiratory mus-
cles and has adverse effects on the
cardiocirculatory system.22
Role of Bacterial Colonization and
Exacerbations
Bacterial colonization and exacerbations (or
acute clinical deterioration) of COPD both
have a role in the progression of small airways
disease.4 Bacterial colonization is aggravated
by reduced clearance anddecreased antimicro-
bial activity of mucus in patients with COPD.4
This can lead to chronic low-grade inflamma-
tion, which at times can increase acutely,mayocp.2021.03.016 3
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leading to an exacerbation.4 Furthermore,
acute exacerbations are often associated with
new strains of colonizing bacteria, supporting
a causative role of bacteria in the onset of exac-
erbations.23 Exacerbations of COPD also
appear to play a part in the airway remodeling
process, by promoting rapid turnover of the
extracellular matrix (including increases in
degradation fragments of collagens I, IV, and
VI and the pro-form of collagen V), increasing
sputum neutrophils and neutrophil proteases,
increasing expression and activity of matrix
metalloproteinases, and dysregulatingprotein-
ase activity.24-27 These effects, in turn, lead to
tissue destruction and reduced mobility of
mucus.4CLINICAL EFFECT
Small airways disease is associated with poor
spirometry results, increased lung hyperinfla-
tion, and poor health status, making the small
airways an important treatment target in
COPD.9 There is also a significant correlation
between small airways disease and quality of
life (measured by the St. George’s Respiratory
Questionnaire) as well as between small air-
ways disease and dyspnea (measured by the
modified Medical Research Council Scale)
(both P<0.01).28
Small airways disease and emphysema are
associated with FEV1 decline, particularly inMayo Clin Proc. n XXXmild-to-moderate COPD.17 Treatments target-
ing the small airways in COPDmay reduce the
rate of emphysema progression.4 In fact,
because small airways disease appears to pre-
cede the onset of emphysema, the develop-
ment of treatments that specifically target
small airways disease has the potential to treat
progression of both airway and parenchymal
disease.14
ASSESSMENT
Small airways disease can be difficult to assess
because of the small size and inaccessibility of
the airways.15 Many methods are complex or
invasive, and overall, there is no unanimously
accepted approach. Different methods of
assessment are described below and summa-
rized in the Supplemental Table (available on-
line at http://www.mayoclinicproceedings.
org), with Figure 3 providing an infographic
overview of these techniques and their outputs.
With small airways disease, traditional
lung function tests may only become
abnormal once there is a significant burden
of disease.5,12,13,15 Hence, although spirom-
etry is the gold standard for diagnosing
COPD, FEV1 is not an adequate measure of
small airways disease.5,12,14,15 Small airways
disease is associated with bronchodilator
responsiveness in terms of volume (forced vi-
tal capacity [FVC]) but not in terms of flow
(FEV1).
9 Indeed, FVC has been used as an in-
direct measure of small airways disease in
several clinical trials.29 Forced expiratory
flow between 25% and 75% of the FVC is
another common measure of small airways
abnormality, though there is conflicting evi-
dence regarding its reliability.12,15 Other mea-
sures of expiratory flow include evaluation of
maximal expiratory flow when 75%, 50%, or
25% of FVC remains.5 The ratio of forced
expiratory volume in 3 and 6 seconds
(FEV3/FEV6) has also emerged as an earlier
and more sensitive marker of small airways
disease compared with other spirometric
measures, with low FEV3/FEV6 found to be
associated with impaired computed tomogra-
phy (CT) scanning measures of small airways
disease in patients with normal FEV1/FVC.
30
Furthermore, the Genetic Epidemiology of
COPD (COPDGene) Study reported that2021;nn(n):1-16 n https://doi.org/10.1016/j.mayocp.2021.03.016
www.mayoclinicproceedings.org
TARGETING SMALL AIRWAYS DISEASE IN COPDpatients with a reduced FEV3/FEV6 had a
higher degree of gas trapping, worse symp-
toms (according to both the St. George’s Res-
piratory Questionnaire and the modified
Medical Research Council Scale), and worse
functional indices (6-minute walk distance)
than patients with FEV3/FEV6 greater than
the lower limit of normal.30,31
Body plethysmographydwhich pro-
vides a sensitive measure of gas trapping
and lung hyperinflationdcan be used to
assess lung volumes, providing measures
such as total lung capacity (TLC), func-
tional residual capacity, inspiratory capac-
ity, and residual volume (RV).12,15 As
TLC is commonly elevated in COPD, the
ratio of RV/TLC may provide a more robustIC at rest
FRC at rest: COPD
FRC at rest: healthy
Healthy
CO
FIGURE 2. Dynamic hyperinflation in COPD. This figu
lung volumes. In COPD, if the small airways are narro
limitation, the inhaled volume of air is greater than th
Accordingly, individuals with COPD often have some
During resting breathing (COPD: green line; healthy
volume and an equal volume is exhaled so that the FRC
COPD. During exertion, agitation, or anxiety, the tidal
with a reduction in expiratory time. Because the inspira
the end-expiratory volume increases with each brea
reduction in IC. This results in an increasing sensation
activity in COPD. COPD, chronic obstructive pulmo
inspiratory capacity.
Mayo Clin Proc. n XXX 2021;nn(n):1-16 n https://doi.org/10.1016/j.
www.mayoclinicproceedings.orgmarker of gas trapping and small airways
disease than RV alone.15 Airways resistan-
cedwhich provides a measure of airway
obstructiondmay also be assessed by
body plethysmography by measuring the
pressure required to drive airflow during
tidal ventilation.5 Diffusing capacity for
carbon monoxide (also known as transfer
factor of the lung for carbon monoxide),
which indirectly measures the degree of
gas transfer from alveoli to pulmonary
capillary blood, has also been found to
correlate with small airways disease.32
Data from ever-smokers in the COPDGene
cohort indicated that functional small air-
ways disease correlates significantly with









re shows the effects of dynamic hyperinflation on
wed or obstructed and there is expiratory airflow
e exhaled volume and air is retained in the lung.
degree of hyperinflation in their lungs, even at rest.
individual: blue line), a breath is inhaled to tidal
remains stable but is still increased in patients with
volume and breathing frequency increase (red line)
tory volume is greater than the expiratory volume,
th, leading to a progressive increase in FRC and
of dyspnea and consequent limitation of physical




monoxide among nonobstructed and
GOLD stage 1-2 individuals (P<0.001 and
P¼0.004, respectively).32
The forced oscillation technique and
impulse oscillometry are techniques that
can be used to determine the mechanical
properties of the lung.5,13-15,33,34 The
forced oscillation technique and impulse
oscillometry work by applying oscillating
pressure variations of varying frequencies
to the lung during normal tidal breathing,
with the resulting pressure and flow
changes measured at the mouth.15 Higher-
frequency signals reflect the contribution
of larger airways, whereas low frequencies
reflect the whole lung; as such, the contri-
bution of the small airways can be found
by comparing the two.15
Inert gas washout techniques such as the
single-breath nitrogen washout test and
multiple-breath nitrogen washout test may
also be used to assess small airways dis-
ease.13 These techniques work by measuring
the efficiency of gas mixing in the lungs,
which varies according to the structure of
the large and small airways and can therefore
give an indication of small airways
disease.5,12,13,15 The sensitivity of the
multiple-breath washout test has been found
in smokers, with evidence of small airways
disease detected from more than 10 pack-
years onward, compared with more than
20 pack-years onward when assessed using
spirometry.35 An analysis of the slope of
phase III, which forms part of the character-
istic trace that is recorded during the single-
breath nitrogen washout test (Figure 3), can
provide further information on the differ-
ences in ventilation in different parts of the
lung.15 Measurement of novel exhaled bio-
markers, including exhaled nitric oxide,
can give an indication of inflammation
(particularly eosinophilic inflammation) in
the lung, including its location within cen-
tral or peripheral airways.12,15
Lung imaging techniques for visualizing
the small airways (Supplemental Table and
Figure 4) include high-resolution CT, which
is increasingly being supplemented by para-
metric image response mapping.5,12-15,36,37
Hyperpolarized helium magnetic resonanceMayo Clin Proc. n XXXimaging is another useful technique for eval-
uating regional lung function, including
assessment of the distribution of ventilation
and morphometry of the distal airways and
lung parenchyma.15 Other imaging tech-
niques include nuclear medicine (scintig-
raphy, single photon emission CT, and
positron emission tomography)15 and func-
tional respiratory imaging, which uses
airway imaging techniques such as CT com-
bined with computational fluid dynamic
simulations to determine patterns of airflow
and inhaled drug deposition.38-40 Another
recent method uses CT imaging techniques
to identify and assess the relative contribu-
tions of emphysematous and nonemphysem-
atous gas trapping, thus helping to assess
different COPD phenotypes.41
Other techniques to assess small airways
are more invasive and typically only used for
research purposes, for example, sputum in-
duction after inhalation of hypertonic saline,
bronchoalveolar lavage, and endobronchial
and transbronchial biopsies.12
For the assessment of dynamic hyperin-
flation and ventilatory limitation, exercise
testing is a commonly used clinical tool
that is easy to implement. Measurement of
tidal exercise flow volume loops can provide
sensitive data on the extent of expiratory
flow limitation, inspiratory flow reserve,
and alterations in dynamic hyperinflation
and tidal volume/inspiratory capacity and
may enable earlier detection of abnormalities
than other approaches.42,43 Constant work
rate endurance protocols are also an effective
patient-centered method to assess the
response to therapeutic interventions in pa-
tients with COPD.44PREVENTION
Although it is not the primary focus of this
article, it is important to note that preven-
tion is the best means to tackle the global
burden of small airways disease and COPD.
This can be achieved by implementing effec-
tive smoking cessation programs and
reducing environmental exposure to biomass
fuels and air pollution; however, this is diffi-
cult to achieve in practice.452021;nn(n):1-16 n https://doi.org/10.1016/j.mayocp.2021.03.016
www.mayoclinicproceedings.org
FIGURE 3. Measurementof small airwaysdisease:physiological techniques.COPD,chronicobstructivepulmonarydisease;CV,closingvolume;
ERV,expiratory reserve volume; FENO, fractional exhalednitric oxide; FEV1/3/6, forcedexpiratory volume in1/3/6 second(s); FRCpleth, functional
residual capacitymeasured using plethysmography; FVC, forced vital capacity; IC, inspiratory capacity; IRV, inspiratory reserve volume;MEF25/50/
75, maximal expiratory flowwhen 25%/50%/75% of forced vital capacity remains; MMEF, maximal mid-expiratory flow; NO, nitric oxide; PEF,
peak expiratory flow; RV, residual volume; SVC, slow vital capacity; TLC, total lung capacity; VT, tidal volume.
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What Treatments Are Available to Target the
Small Airways?
Directing drugs to the small airways via the
inhaled route has a number of advantages
compared with oral or intravenous routes.
For example, smaller drug doses can be
used, the onset of action is more rapid, and
the incidence of adverse effectsdparticularly
those of corticosteroidsdis reduced.46,47
The choice of both the drug molecule
and the inhaler device is critical, particularlyMayo Clin Proc. n XXXwhen considering how best to enhance drug
deposition at the site of disease. As well as
the total dose of drug delivered to the lungs,
the regional deposition pattern within the
lungs is an important factor.47,48 As most
inhaled therapies do not sufficiently reach
the small airways, it is necessary to improve
the precision of drug deposition to increase
the efficiency and effectiveness of inhaled
drug delivery.49,50 Different therapeutic op-
tions with the potential to target the small
airways are described below and are summa-
rized in the Table.14,57-812021;nn(n):1-16 n https://doi.org/10.1016/j.mayocp.2021.03.016
www.mayoclinicproceedings.org
FIGURE 4. Measurement of small airways disease: imaging techniques. COPD, chronic obstructive pulmonary disease. aReprinted from
Contoli M, et al. Allergy. 2010;65(2):141-151. https://doi.org/10.1111/j.1398-9995.2009.02242.x. ª 2009 John Wiley & Sons A/S.51
bReprinted with permission from Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation. Kirby M, et al. J COPD F.
2014;1(2):200-211. http://doi.org/10.15326/jcopdf.1.2.2014.0136.52 cAdapted with permission of the American Thoracic Society.
Copyright ª 2020 American Thoracic Society. All rights reserved. Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and
bronchodilator response as a function of ß2-agonist particle size. Am J Respir Crit Care Med. 2005;172(12):1497-1504. The American
Journal of Respiratory and Critical Care Medicine is an official journal of the American Thoracic Society. Readers are encouraged to read the
entire article for the correct context at https://doi.org/10.1164/rccm.200410-1414OC. The authors, editors, and the American Thoracic
Society are not responsible for errors or omissions in adaptations.48 dReproduced with permission from Milne M, King GG. J Thorac Dis.
2014;6(11):1570-1585. https://doi.org/10.3978/j.issn.2072-1439.2014.11.30. Copyright ª 2020 AME Publishing Company.53 eAdapted
with permission of the American Thoracic Society. Copyright ª 2020 American Thoracic Society. All rights reserved. Subramanian DR,
et al. 2012. Assessment of pulmonary neutrophilic inflammation in emphysema by quantitative positron emission tomography. Am J
Respir Crit Care Med. 2012;186:1125-1132. The American Journal of Respiratory and Critical Care Medicine is an official journal of the
American Thoracic Society. Readers are encouraged to read the entire article for the correct context at https://doi.org/10.1164/rccm.
201201-0051OC. The authors, editors, and the American Thoracic Society are not responsible for errors or omissions in adaptations.54
fImages from Burrowes KS, et al. J Transl Med. 2014;12:S5. Published by BioMed Central Ltd. This work is licensed under a Creative
Commons Attribution (CC BY) 4.0 License.55 gImages from Occhipinti M, et al. Aging Dis. 2017;8(4):471-485. Published by Aging and
Disease. This work is licensed under a Creative Commons Attribution (CC BY) License.56
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TABLE. Therapeutic Options to Target Small Airways Disease
Novel formulations Mechanism of action
Extrafine particle ICS/LABA formulations14,57-65 d Extrafine particle size enhances delivery to small (as well
as large) airways
d Beclomethasone dipropionate þ formoterol fumarate
d Beclomethasone dipropionate þ formoterol
fumarate þ glycopyrronium bromide
Co-suspension LAMA/LABA formulation (Bevespi
Aerosphere)66,67
d Co-suspension delivery technology used to formulate
glycopyrronium and formoterol fumarate dihydrate
together in MDI enables the uniform delivery of both
treatments
d Glycopyrrolate/formoterol fumarate, formulated using
a novel co-suspension delivery technology for
administration via MDI
Extrafine particle ICS68 d Extrafine particle size enhances delivery to small (as well
as large) airways
d Extrafine beclomethasone
Novel inhalers/inhalation systems Mechanism of action
Respimat Soft Mist inhaler69-73 d Respimat droplets deposit more uniformly in the
different lung regions compared with particles from
dry powder inhalers
d Respimat exhibited a higher proportion of particles
reaching all parts of the lung than did DPIs
Adaptive Aerosol Delivery (AAD) system74 d Adapts to changes in patient’s breathing pattern and
pulses aerosol during the inspiratory part of the
breathing cycle
AKITA inhalation system75 d Uses individualized controlled inhalation to optimize
the inhalation maneuver of the patient
Other agents in development Mechanism of action
Inhaled antibiotics76 d Combined antimicrobial and anti-inflammatory effects
Alpha-1 antiprotease77,78 d Inhibition of proteases involved in the progression of
disease
Anti-inflammatory compounds, eg, monoclonal
antibodies79,80
d Target molecules involved in the inflammatory cascade
such as cytokines
Mucolytic agents81 d Reduce viscosity of the sputum; antioxidant effects
DPI, dry powder inhaler; ICS, inhaled corticosteroid; LABA, long-acting b2-agonist; LAMA, long-acting muscarinic antagonist; MDI,
metered-dose inhaler.
MAYO CLINIC PROCEEDINGS
10Drug Formulations Optimized to Reach the
Small Airways
Recent advances in inhaled drug delivery
have improved delivery of aerosolized med-
icine to the small airways.46 Many factors
can influence the deposition of medical
aerosols in the lung, including characteris-
tics such as size, density, and charge of
drug particles (with smaller particles being
preferable), lipophilicity/hygroscopicity of
formulation, and speed and duration of
aerosol spray (with slower inhalation flow
being preferable).46,82 Patient-specific fac-
tors are also important, including the pa-
tient’s breathing pattern and inhalationMayo Clin Proc. n XXXtechnique (inspiratory flow, inhaled vol-
ume, and breath-hold pause), severity of
disease, and device acceptance and adher-
ence.46 In particular, particle size plays a
key role in determining the fate of the aero-
solized medicine within the respiratory
tract, with larger particles being deposited
in the oropharynx, trachea, and upper
bronchial tree and smaller particles able
to reach the distal airways.14,46 To ease dif-
ferentiation, particle size can be classified
as extrafine, fine, or coarse according to
whether the mass median aerodynamic
diameter is less than 2.1, 2.1 to 5, or greater
than 5 mm, respectively.822021;nn(n):1-16 n https://doi.org/10.1016/j.mayocp.2021.03.016
www.mayoclinicproceedings.org
TARGETING SMALL AIRWAYS DISEASE IN COPDRecently developed inhaled formulations
that optimize delivery to the small airways
include extrafine inhaled corticosteroid
(ICS), ICS/long-acting b2-agonist (LABA)
formulations (eg, ciclesonide and beclome-
thasone dipropionate/formoterol fumarate),
and ICS/LABA/long-acting muscarinic antag-
onist (LAMA) formulations (eg, beclometha-
sone dipropionate/formoterol fumarate/
glycopyrronium bromide). These agents
have been evaluated for use in small airways
disease both in COPD14,57,58,65 and in
asthma.59-64,83 A novel fixed-dose LAMA/
LABA combination of glycopyrrolate/formo-
terol fumarate has also been formulated us-
ing co-suspension delivery technology for
administration via a pressurized metered-
dose inhaler (pMDI; Bevespi Aerosphere;
AstraZeneca, Cambridge, UK).66,67 Clinical
findings from a scintigraphy study reported
that doses of glycopyrrolate/formoterol
fumarate pMDI were deposited in both cen-
tral and peripheral lung regions,84 revealing
that this approach can successfully target
the small airways and provide a further treat-
ment option for patients who prefer to use a
pMDI, such as those who may be unable to
achieve the minimum inspiratory flow rate
necessary to use a dry powder inhaler
(DPI).67
For patients who require ICS in addition to
bronchodilator therapy, it may be beneficial to
target the small airways with extrafine particle
formulations.68 The FOsteR 48-Week trial to
reduce exAceRbations in COPD (FORWARD)
study reported that compared with formoterol
alone, extrafine beclomethasone/formoterol
significantly reduced the exacerbation rate
and improved lung function inpatientswith se-
vere COPD and a history of exacerbations.85 In
another study by Tzani et al,86 extrafine beclo-
methasone/formoterol significantly reduced air
trapping and dyspnea in patients with COPD
and lung hyperinflation when compared with
fluticasone/salmeterol. Furthermore, findings
from the randomized controlled trial TRILOGY
suggest that triple therapywith extrafine beclo-
methasone dipropionate/formoterol/glycopyr-
ronium bromide fixed-dose combination can
reduce moderate and severe exacerbations
more effectively than ICS/LABA combinationMayo Clin Proc. n XXX 2021;nn(n):1-16 n https://doi.org/10.1016/j.
www.mayoclinicproceedings.orgtherapy.87 There is also evidence that extrafine
beclomethasone at lower doses is equivalent to
fluticasone at higher doses in terms of reducing
exacerbations, with improved treatment stabil-
ity over a 2-year period, suggesting greater lung
deposition of extrafine beclomethasone to the
small airways.68 This is supported by a recent
study, which used a model approach based on
functional respiratory imaging computer simu-
lations.88 This revealed that extrafine beclome-
thasone dipropionate/formoterol fumarate/
glycopyrronium bromide had higher periph-
eral deposition of all three components (ICS,
LABA, and LAMA) compared with a non-
extrafine formulation of fluticasone furoate/
vilanterol/umeclidiniumon the basis of profiles
from patients with moderate-to-very severe
COPD.88 It must be noted, however, that
research supporting the benefits of enhanced
drug delivery to the small airways on patient-
centered outcomes is limited.
Using lower doses of ICS is also likely to
be associated with a reduced risk of adverse
events. Findings from a real-life COPD study
suggest that patients taking extrafine particle
ICS have a lower risk of pneumonia than
those taking fine-particle ICS.89 In addition,
data from patients with asthma suggest that
extrafine particle ICS is associated with an
improved chance of asthma control and
lower exacerbation rates at significantly
lower ICS doses as compared with fine parti-
cle ICS.90
Inhalers Optimized to Reach the Small
Airways
Conventional pMDIs and most DPIs emit
drug particles that are too large to effectively
target the small airways.49 However, some
newer DPIs such as the NEXThaler (Chiesi,
Manchester, UK) have been developed to
deliver extrafine particles that can reach
them.91 Inhaler technique also has an impor-
tant role in ensuring efficient delivery of
drug.92
Inhaler delivery efficiency is another
important factor affecting the level of deposi-
tion in the small airways.69 For example, the
Respimat Soft Mist inhaler (Boehringer
Ingelheim, Ingelheim, Germnay) produces
aerosol droplets with a diameter of 1 tomayocp.2021.03.016 11
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125.8 mm to ensure efficient lung deposition
while avoiding loss of small droplets during
exhalation.70 The fine particle fraction is
approximately 75% forRespimatwithmost for-
mulations (range, 65%-80%), representing
nearly double the value reported for aerosols
generated by conventional pMDIs and
DPIs.70,93 Coupled with the low velocity and
long generation time of the aerosol, this means
thatmore of the emitted dose is deposited in the
lungs and less in the oropharynx compared
with aerosols from other inhalers.70-73,94 This
is supported by a combined in vitro/in silico
model of COPD, in which Respimat exhibited
the lowest throat deposition and the highest
deposition in the whole lung and in different
lung generations, compared with the tested
DPIs.69 Further support has been provided by
an in vivo scintigraphy study, which revealed
similar Respimat deposition data to the
in vitro analyses.95
Novel aerosol delivery systems such as
the Adaptive Aerosol Delivery (AAD; Phi-
lips Respironics, Murrysville, PA) system
may also be of use in small airways disease.
These are designed to continuously adapt
to changes in the patient’s breathing pattern
so that they pulse aerosol only during the
inspiratory part of the breathing cycle, thus
eliminating waste and ensuring precise aero-
sol delivery.74 Another aerosol delivery sys-
tem that actively controls the entire
inhalation maneuver of the patient is the
AKITA inhalation system (Activaero,
Gemünden, Germany).75 This uses informa-
tion delivered by a computer-controlled
compressor programmed from the patient’s
own individual lung function data.75
Drugs Aimed at Improving Small Airway
Function
In addition, there is significant ongoing inter-
est in the development and application of
both existing and novel drugs to target the
small airways, including inhaled antibiotics,
anti-inflammatory compounds, monoclonal
antibodies, antiprotease therapy, and muco-
lytic agents.76-81,96
Macrolide antibiotics, which are
commonly used in cystic fibrosis and otherMayo Clin Proc. n XXXforms of bronchiectasis, may be of use in
patients with small airways disease caused
by underlying infection and inflamma-
tion.96 Efforts are underway to develop
inhaled formulations of these drugs, which
may have a lower risk of systemic toxicity,
for example, QT prolongation and
ototoxicity.76
Mucolytic agents are associated with
modest reductions in exacerbations and im-
provements in quality of life in some
studies81,97 and could have a role in long-
term management of COPD. In a study
comparing the mucolytic agent N-acetyl
cysteine with placebo, N-acetyl cysteine
was found to provide significantly greater
improvements in measures of small airways
function, forced expiratory flow at 25% to
50%, and forced oscillation technique.81
FUTURE DIRECTIONS
Despite growing insight into small airways
disease, a number of questions have so far
remained unanswered in our understanding
of the area. Early detection remains the key
barrier, although we have outlined several
new approaches that have the potential to
achieve this goal. Critically, if detected early,
treatment with therapy options designed to
target small airways should help slow disease
progression, reduce symptoms, and help pa-
tients maintain their activities. It may there-
fore be beneficial to further investigate
whether the ability to target treatments to
the lung periphery and increase lung deposi-
tion could slow disease progression in pa-
tients with COPD and thereby become a
viable treatment option for patients who
have small airway involvement and early
signs of COPD.
Recent increases in understanding con-
cerning the inflammatory pathways underly-
ing COPD are also giving rise to the
development of targeted therapies, such as bi-
ologics and small molecules.79 As small air-
ways are the major site of obstruction,
caused by airway remodeling and accumula-
tion of inflammatory exudates,79 treatments
targeted to the small airways may be particu-
larly beneficial. However, despite significant2021;nn(n):1-16 n https://doi.org/10.1016/j.mayocp.2021.03.016
www.mayoclinicproceedings.org
TARGETING SMALL AIRWAYS DISEASE IN COPDinterest in cytokines and chemokines as a
therapeutic target in COPD, there is a need
for novel targets that are more specific and
have a reduced adverse effect profile.80
Another possible target in COPD is to
address protease-antiprotease imbalance,
which may be involved in the pathology of
small airways disease. Recent evidence sug-
gests that enhanced protease activity is asso-
ciated with small airway remodeling and that
serine protease inhibitors may be a potential
therapeutic target for small airways disease.
Studies are needed that compare outcomes
obtained by traditional management of COPD
(ie, according to GOLD recommendations)
with those based on small airway-directed
management. Moreover, evidence is required
to find the possible role of new drugs in the
development for treating small airways dis-
ease, as well as novel drug formulations, in-
halers, and inhalation devices. It will be of
particular interest to discern whether the pro-
gression of COPD can be slowed in some pa-
tients after they stop smoking by targeting
the inflammation in the small airways.
It is important to recognize that the char-
acterization and targeted treatment of small
airways is just one component of a broader
strategy to evaluate the phenotypic varia-
tions of patients with COPD to provide
them with the most effective and appropriate
targeted therapy. This comprehensive diag-
nostic and management strategy includes
many different modalities, including immu-
nizations, oxygen therapy, lung volume
reduction surgery, bronchoscopic lung vol-
ume reduction, pulmonary rehabilitation,
mindfulness, and breathing techniques, in
addition to pharmacological therapy. These
are discussed in more detail elsewhere.7
Finally, we have concentrated here on
treating disease, but it is also important to
consider prevention of COPD by reducing
environmental exposure to biomass fuels in
third world countries and reducing particulate
and gaseous air pollution in major metropol-
itan areas.
CONCLUSION
Both preventable and treatable, small airways
disease has important clinical consequencesMayo Clin Proc. n XXX 2021;nn(n):1-16 n https://doi.org/10.1016/j.
www.mayoclinicproceedings.orgif left unchecked. Small airways disease is asso-
ciated with poor spirometry results, increased
lung hyperinflation, and poor health status,
making the small airways an important treat-
ment target in COPD. Further advances in
our ability to assess the extent of small airways
involvement, as well as the use of novel drugs,
formulations, and inhalers that target the small
airways, will help improve our management of
small airways disease in patients with COPD.ACKNOWLEDGMENTS
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